Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today
Artiva Biotherapeutics presented positive Phase 2a data for its lead asset AlloNK at EULAR 2026, showing a 71% ACR50 response rate at six months in refractory rheumatoid arthritis patients. The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to AlloNK plus rituximab for refractory RA, supporting the company's planned registrational strategy and providing access to expedited development benefits.
Key figures
- Drug Name
- AlloNK (AB-101)
- Phase Of Trial
- Phase 2a
- Safety patients
- 55
- Acr50 response rate
- 71%
- Grade3 infection rate
- 2%
- Ssc rcris25 achievement
- 100%
- Ssc rcris50 achievement
- 50%
- Total patients presented
- 31
- Ssc mean mrss improvement
- 9.5
- Sjd mean clinessdai baseline
- 16.1
- Sjd mean clinessdai followup
- improvement noted
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.